GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Common Stock

CureVac NV (WBO:CVAC) Common Stock : €26.9 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Common Stock?

CureVac NV's quarterly common stock increased from Jun. 2024 (€26.9 Mil) to Sep. 2024 (€26.9 Mil) but then stayed the same from Sep. 2024 (€26.9 Mil) to Dec. 2024 (€26.9 Mil).

CureVac NV's annual common stock increased from Dec. 2022 (€23.4 Mil) to Dec. 2023 (€26.9 Mil) and increased from Dec. 2023 (€26.9 Mil) to Dec. 2024 (€26.9 Mil).


CureVac NV Common Stock Historical Data

The historical data trend for CureVac NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Common Stock Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 21.66 22.45 23.40 26.88 26.92

CureVac NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.88 26.92 26.92 26.92 26.92

CureVac NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


CureVac NV Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.